{"id":11665,"date":"2026-10-28T13:49:01","date_gmt":"2026-10-28T10:49:01","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?ism_drug=hydralazine-hidralazin"},"modified":"2026-10-28T13:49:02","modified_gmt":"2026-10-28T10:49:02","slug":"hydralazine-hidralazin","status":"publish","type":"ism_drug","link":"https:\/\/www.ortaakarsu.net\/?ism_drug=hydralazine-hidralazin","title":{"rendered":"Hydralazine (Hidralazin)"},"content":{"rendered":"<p><strong>Hydralazine (Hidralazin)<\/strong>, Hidralazin etken maddesinin uluslararas\u0131 ad\u0131 \u00fczerinden haz\u0131rlanm\u0131\u015f bilgi sayfas\u0131d\u0131r.<\/p>\n<p><strong>Uygulama kapsam\u0131:<\/strong> A\u011f\u0131zdan. Doz ve art\u0131rma aral\u0131klar\u0131 ki\u015fiye g\u00f6re ayarlan\u0131r; kalp yetersizli\u011finde ba\u015flang\u0131\u00e7 ve ila\u00e7 kesme plan\u0131 uzman g\u00f6zetimi gerektirir. Farkl\u0131 g\u00fc\u00e7 ve farmas\u00f6tik formlar\u0131n birbirinin yerine kullan\u0131labilece\u011fi varsay\u0131lmamal\u0131d\u0131r.<\/p>\n<h2>T\u00fcrkiye\u2019de yurt d\u0131\u015f\u0131ndan temin kayd\u0131<\/h2>\n<p><a href=\"https:\/\/www.teb.org.tr\/docs\/3aac322e-7bec-4df1-a37f-0dd1757bed11\/yurtdisi-aktif-ilac-listesi\" rel=\"noopener\">TEB\u2019in 2 Ekim 2026 tarihli \u00fcr\u00fcn listesinde<\/a> bu etken maddeyi i\u00e7eren \u00fcr\u00fcn kay\u0131tlar\u0131 do\u011fruland\u0131: HYDRALAZINE HCL 20 MG 25 VIAL; APRESOLINE FOR INJECTION 20 MG 10 AMP; HYDRALAZINE 25 MG 56 TB. <a href=\"https:\/\/www.titck.gov.tr\/dinamikmodul\/126\" rel=\"noopener\">T\u0130TCK\u2019nin 28 Eyl\u00fcl 2026 tarihli etken madde listesi<\/a> ayr\u0131ca kontrol edildi. Temin ko\u015fullar\u0131 hastaya, re\u00e7eteye, endikasyona ve gerekli onaylara g\u00f6re de\u011fi\u015febilir; listede yer almak g\u00fcncel stok veya geri \u00f6deme garantisi de\u011fildir. Klinik kullan\u0131m alan\u0131 a\u015fa\u011f\u0131daki \u00fcr\u00fcn belgesine g\u00f6re a\u00e7\u0131klan\u0131r; temin listesindeki tan\u0131 ko\u015fullar\u0131 tek ba\u015f\u0131na yeni bir klinik endikasyon olu\u015fturmaz.<\/p>\n<h2>Bilimsel ara\u015ft\u0131rmalardan bilgiler<\/h2>\n<p>Yedi sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fcde oral hidralazin, konvansiyonel propranolol\u00fcn sistemik kullan\u0131labilirli\u011fini de\u011fi\u015fken \u00f6l\u00e7\u00fcde art\u0131rd\u0131; \u00e7al\u0131\u015fma klinik dozun kendili\u011finden de\u011fi\u015ftirilmesini desteklemez. <a href=\"https:\/\/doi.org\/10.1038\/clpt.1980.103\" rel=\"noopener\">Interaction between oral propranolol and hydralazine<\/a><\/p>\n<p>Alt\u0131 sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fcyle yap\u0131lan k\u00fc\u00e7\u00fck \u00e7al\u0131\u015fmada hidralazin, uzat\u0131lm\u0131\u015f sal\u0131ml\u0131 propranolol\u00fcn tepe d\u00fczeyini veya toplam maruziyetini de\u011fi\u015ftirmedi; konvansiyonel \u00fcr\u00fcnle bildirilen etki her sal\u0131m formuna ayn\u0131 b\u00fcy\u00fckl\u00fckte genellenemez. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/6743474\/\" rel=\"noopener\">Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: Evidence implicating substrate delivery rate as a determinant of presystemic drug interactions<\/a><\/p>\n<h2>Kaynaklar<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.medicines.org.uk\/emc\/product\/6707\/smpc\" rel=\"noopener\">ADVANZ Apresoline\/Hydralazine 25 mg oral tablets, UK SmPC, emc 02.07.2026<\/a> (ADVANZ Apresoline\/Hydralazine 25 mg oral tablets, UK SmPC, emc 02.07.2026)<\/li>\n<li><a href=\"https:\/\/doi.org\/10.1038\/clpt.1980.103\" rel=\"noopener\">Interaction between oral propranolol and hydralazine<\/a> \u2014 A. J. McLean; H. Skews; A. Bobik; F. J. Dudley; Clinical Pharmacology &amp; Therapeutics; 1980; DOI: 10.1038\/clpt.1980.103 (1980;27(6):726\u2013732)<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/6743474\/\" rel=\"noopener\">Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: Evidence implicating substrate delivery rate as a determinant of presystemic drug interactions<\/a> \u2014 A. J. Byrne; J. J. McNeil; P. M. Harrison; W. Louis; A. M. Tonkin; A. J. McLean; British Journal of Clinical Pharmacology; 1984; DOI: 10.1111\/j.1365-2125.1984.tb02427.x (1984;17(Suppl1):45S\u201350S)<\/li>\n<\/ul>\n<p>Kaynak kontrol\u00fc: <time datetime=\"2026-10-28\">28 Ekim 2026<\/time>. Bu tarih, bir hekim veya eczac\u0131 taraf\u0131ndan klinik inceleme yap\u0131ld\u0131\u011f\u0131 anlam\u0131na gelmez. Ki\u015fisel tedavi plan\u0131 i\u00e7in kullan\u0131lan \u00fcr\u00fcn\u00fcn g\u00fcncel talimat\u0131 ve sa\u011fl\u0131k uzman\u0131n\u0131n de\u011ferlendirmesi esas al\u0131n\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hydralazine (Hidralazin), Hidralazin etken maddesinin uluslararas\u0131 ad\u0131 \u00fczerinden haz\u0131rlanm\u0131\u015f bilgi  [&#8230;]<\/p>\n","protected":false},"featured_media":0,"template":"","ism_etken_madde":[1283],"class_list":["post-11665","ism_drug","type-ism_drug","status-publish","hentry","ism_etken_madde-hidralazin"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/11665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/ism_drug"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/11665\/revisions"}],"predecessor-version":[{"id":11666,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/11665\/revisions\/11666"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11665"}],"wp:term":[{"taxonomy":"ism_etken_madde","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fism_etken_madde&post=11665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}